Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific share repurchase transaction executed on June 6, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 757,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,590 pence per share; lowest price paid was 1,581 pence per share.
- Treasury Holdings (Settled): 497,151,414 shares (9.29% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,547,414 shares (10.29% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,853,633,440 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 757,500 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.29% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (497,151,414 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights, noting that 4,853,633,440 shares are in issue excluding Treasury shares.
- Check the settlement status of the 757,500 shares purchased on June 6, 2014, to reconcile the difference between settled and total Treasury holdings.